mito-extra® - medac GmbH

58
Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Boeken Kruger C, De
Pauw M, Sylvester RJ and the EORTC
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma:
results of 2 European organisation for research and treatment of cancer
randomized trials with Mitomycin and doxorubicin comparing early versus delayed
instillations and short-term versus long-term treatment
J-Urol, 1995; 153: 934 - 941
Brausi M, Campo B, Pizzocaro G, et al.
Intravesical electromotive administration of drugs for treatment of superficial bladder
cancer: a comparative phase II study
Urology, 1998; 51: 506-509
Brown JM
The Hypoxic Cell: A target for selective cancer therapy-18th Bruce F. Cain
Memorial Award Lecture
Cancer Res. 1999; 59: 5863-5870
Burnand KG, Boyd PJR, Mayo ME, Shuttleworth KED, Lloyd-Davies RW
Single dose intravesical Thiotepa as an adjuvant to Cystodiathermy in the treatment
of transitional cell bladder cancer
Br-J-Urol, 1976; 48: 55-59
Cliff AM, Romaniuk CS, Parr NJ,
Perivesical inflammation after early Mitomycin instillation
BJU-International, 2000; 85: 556-557
Conrad S, Friedrich MG, Schwaibold H, Pichlmeier U, Schildt K, Wolf N,
Huland H
Long term prophylaxis with Mitomycin (MCC) further reduces tumor recurrence
compared to short term prophylaxis with MMC or Bacillus Calette-Guerin (BCG)
J-Urol, 2004; 171, 4, Suppl.: Abstr. 271
da Silva FC, Ferrito F, Brandao T, Santos A
4'-epidoxorubicin versus Mitomycin intravesical chemoprophylaxis of superficial
bladder cancer.
Eur Urol, January 1, 1992; 21(1): 42-4.
De Bruijn EA, Sleeboom HP, van Helsdingen PJRO, van Oosterom AT,
Tjaden UR, Maes RAA
Pharmacodynamics and pharmacokinetics of intravesical Mitomycin upon different
dwelling times
Int-J-Cancer 1992; 51: 359-364
DeBruyne FMJ, van der Meijden APM, Geboers ADH et al.
BCG (RIVM) vs. Mitomycin intravesical therapy in superficial bladder cancer. First
results of randomized prospective trial.
Urology 1988; 30: 20
De Furia MD, Bracken RB, Johnson DE, Soloway MS, Merrin CE, Morgan LR,
Miller HC, Crooke ST.
Phase I-II study of Mitomycin topical therapy for low-grade, low stage transitional
cell carcinoma of the bladder: an interim report.
Cancer Treat Rep. 1980; 64(2-3):225-30.
Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R,
Vespasiani G
Intravesical electromotive Mitomycin versus passive transport Mitomycin for high
risk superficial bladder cancer: A prospective randomized study
J-Urol 2003; 170: 777-782
Di Stasi SM, Giannantoni A, Stephen RL, Virgili G, Giurioli A, Storti L
Zampa G, Vespasiani G
Sequential intravesical Bacillus Calmette-Guerin and electromotive Mitomycin-C
for high risk superfical bladder cancer: A prospective controlled stude\NLN\
J-Urol 2004; 171, 4, Suppl.: Abstr. 278